Retinopathy of prematurity (ROP), a disorder of halted or pathological retinal vascular growth was originally described by T. L. Terry, MD, as retrolental fibroplasia in 1942.1 During the past 7 decades, our care for preterm infants with ROP has improved substantially. Milestone studies, including the International Classification of Retinopathy of Prematurity (ICROP), Cryotherapy for Retinopathy of Prematurity (CRYO-ROP), Laser ROP, and Early Treatment of Retinopathy for Prematurity (ETROP) studies, have established our current screening criteria and treatment protocols and prevented blindness in many of the affected infants.2 This is especially relevant as the prevalence of ROP has increased in both low-income and high-income countries with advances in neonatal care and increased survival of very preterm infants.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chen X. Caring for Infants Undergoing Screening for Retinopathy of Prematurity. JAMA Ophthalmol. 2019;137(11):1273–1274. doi:10.1001/jamaophthalmol.2019.3377
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: